Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHASE 3 RESULTS POSITION TELITACICEPT AS POTENTIAL BEST-IN-DISEASE PROFILE IN PRIMARY SJGREN'S DISEASE TELITACICEPT DEMONSTRATED A FAVORABLE SAFETY PROFILE VOR EVALUATING TIMING OF GLOBAL PHASE 3 CLINICAL STUDY IN PRIMARY SJGREN'S DISEASE DATA ANTICIPATED TO BE PRESENTED AT AN UPCOMING MEDICAL CONFERENCE CAMBRIDGE, MASS., AUG. 13, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), ACHIEVED THE PRIMARY ENDPOINT IN A PHASE 3 CLINICAL STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH PRIMARY SJGREN'S DISEASE.

TELITACICEPT ACHIEVED PRIMARY ENDPOINT IN PHASE 3 CLINICAL STUDY FOR PRIMARY SJGREN'S DISEASE WITH TELITACICEPT, A DUAL BAFF/APRIL INHIBITOR

EXPERIENCED COMMERCIAL LEADER TO SHAPE LAUNCH STRATEGY AND GLOBAL MARKET READINESS FOR TELITACICEPT AND FUTURE PIPELINE OPPORTUNITIES EXPERIENCED COMMERCIAL LEADER TO SHAPE LAUNCH STRATEGY AND GLOBAL MARKET READINESS FOR TELITACICEPT AND FUTURE PIPELINE OPPORTUNITIES

VOR BIO APPOINTS SEASONED BIOTECH EXECUTIVE DALLAN MURRAY AS CHIEF COMMERCIAL OFFICER

- NEW BOARD MEMBERS BRING DECADES OF EXPERIENCE IN COMPANY BUILDING, CORPORATE STRATEGY, COMMERCIALIZATION, AND BUSINESS DEVELOPMENT

VOR BIO APPOINTS BIOTECH INDUSTRY LEADERS ALEXANDER (BO) CUMBO AND MICHEL DETHEUX, PH.D. TO BOARD OF DIRECTORS

CAMBRIDGE, MASS., JULY 18, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, EFFECTIVE AS OF JULY 17, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED QING ZURAW, M.D., THE COMPANY'S CHIEF DEVELOPMENT OFFICER, 4,373,040 STOCK OPTIONS AND 937,080 RESTRICTED STOCK UNITS (RSUS) IN CONNECTION WITH THE COMMENCEMENT OF HER EMPLOYMENT. THE FOREGOING STOCK OPTION AND RSU AWARDS WERE GRANTED AS A MATERIAL INDUCEMENT TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

CAMBRIDGE, MASS., JULY 17, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF QING ZURAW, M.D., M.P.H., M.B.A., AS CHIEF DEVELOPMENT OFFICER, EFFECTIVE IMMEDIATELY.

VOR BIO APPOINTS QING ZURAW, M.D. AS CHIEF DEVELOPMENT OFFICER

CAMBRIDGE, MASS., JULY 10, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OFSANDY MAHATME ASCHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER, EFFECTIVE JULY 9, 2025.

VOR BIO APPOINTS VETERAN BIOTECH EXECUTIVE SANDY MAHATME AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER

CAMBRIDGE, MASS., JULY 01, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, EFFECTIVE AS OF JUNE 26, 2025, THE BOARD OF DIRECTORS GRANTED JEAN-PAUL KRESS, THE COMPANY'S CHIEF EXECUTIVE OFFICER, AN OPTION TO PURCHASE 83,296,638 SHARES OF VOR BIO'S COMMON STOCK IN CONNECTION WITH THE COMMENCEMENT OF HIS EMPLOYMENT. THE FOREGOING STOCK OPTION WAS GRANTED AS A MATERIAL INDUCEMENT TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WAS GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORT INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

CAMBRIDGE, MASS., JUNE 25, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A PRIVATE PLACEMENT IN PUBLIC EQUITY FINANCING (THE PIPE) THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $175 MILLION, BEFORE DEDUCTING EXPENSES.

VOR BIO ANNOUNCES $175 MILLION PRIVATE PLACEMENT

-VOR BIO RECEIVES EX-GREATER CHINA RIGHTS TO DEVELOP AND COMMERCIALIZE TELITACICEPT, A NOVEL, DUAL-TARGET RECOMBINANT FUSION PROTEIN IN GLOBAL PHASE 3 DEVELOPMENT FOR GENERALIZED MYASTHENIA GRAVIS -REMEGEN RECEIVES INITIAL PAYMENT OF $125 MILLION CONSISTING OF AN UPFRONT PAYMENT OF $45 MILLION PLUS $80 MILLION OF WARRANTS, POTENTIAL REGULATORY AND COMMERCIAL MILESTONES EXCEEDING $4 BILLION, AS WELL AS TIERED ROYALTIES -SEASONED BIOPHARMA LEADER, JEAN-PAUL KRESS, MD, APPOINTED AS CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, BRINGING PROVEN TRACK RECORD IN CLINICAL DEVELOPMENT, COMMERCIALIZATION, AND STRATEGIC GROWTH CAMBRIDGE, MASS., JUNE 25, 2025 (GLOBE NEWSWIRE) -- VOR BIO, INC. (NASDAQ: VOR) AND REMEGEN CO., LTD.

VOR BIO ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH REMEGEN FOR LATE-STAGE AUTOIMMUNE ASSET

CAMBRIDGE, MASS., MAY 08, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE CELL AND GENOME ENGINEERING COMPANY, TODAY ANNOUNCED THAT, BASED ON CURRENTLY AVAILABLE CLINICAL DATA FROM ITS KEY CLINICAL PROGRAMS AND A CHALLENGING FUNDRAISING ENVIRONMENT, THE BOARD OF DIRECTORS HAS APPROVED THE INITIATION OF A PROCESS TO EXPLORE A RANGE OF STRATEGIC ALTERNATIVES AIMED AT MAXIMIZING BOTH NEAR- AND LONG-TERM SHAREHOLDER VALUE.

VOR BIO ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE

VCAR33 CLINICAL DATA UPDATE PLANNED FOR FIRST HALF OF 2025 AND TREM-CEL + MYLOTARG CLINICAL DATA UPDATE PLANNED FOR SECOND HALF OF 2025 ANTICIPATE INITIATION OF THE FIRST TREM-CEL+VCAR33 TREATMENT SYSTEM CLINICAL TRIAL IN SECOND HALF OF 2025 $55.6 MILLION PRIVATE PLACEMENT COMPLETED IN DECEMBER 2024 CAMBRIDGE, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE CELL AND GENOME ENGINEERING COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE-MONTH PERIOD AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE.

Vor Biopharma Inc.

VOR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vor Biopharma Inc.

VOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VOR